Breaking Research News from sources other than Breastcancer.org
Comments
-
wow, that's great news
0 -
Wow that is amazing. Wonder if there is application after diagnosis/treatment with stage 1 to determine if further years of hormonal therapy needed?
0 -
elenas401 - that is great news for ErSO. I wonder if Bayer did that press release in July just to create a buzz to increase the value of their stock. They probably thought investors would jump on it, but didn't think they would be bombarded by a large gang of menopausal breast cancer patients! I hope Systems Oncolgy succeeds without them. It would be wonderful if this drug becomes a game changer for us. Even if not a cure, perhaps better quality of life and long term remission could be achieved.
Were you able to try the Alpha Dart treatment you mentioned?
0 -
Study compares spiral breast CT, digital mammography
Researchers found that patients who underwent spiral breast CT experienced a significant reduction in discomfort and pain, especially among premenopausal women, compared with digital mammography. The findings, published in the European Journal of Radiology, also showed that using SBCT led to a "favorable" interrater agreement among radiologists and was able to consistently detect microcalcifications at a radiation dose that is comparable to digital mammography.
Full Story: Health Imaginghttps://www.healthimaging.com/topics/diagnostic-screening/patients-prefer-spiral-breast-ct-over-dm
{No charge for access to reporting.}
0 -
Age Distributions of Breast Cancer Diagnosis and Mortality by Race and Ethnicity
- The authors used data from the SEER database to identify trends in breast cancer diagnosis and mortality by race and ethnicity. Minority women were 72% more likely to be diagnosed with invasive breast cancer and 58% more likely to be diagnosed with advanced breast cancer at young ages compared with white women. Minority women were also 127% more likely to die of breast cancer at a young age.
- Minority women are disproportionately impacted by advanced breast cancer at a young age, and this should be considered when developing screening guidelines for breast cancer.
DOI: 10.1002/cncr.33846{Free access to reporting/summary and to journal article.}0 -
elenas401, can you send the link to that article? cant find anything
0 -
Anyone interested in enrolling in the op-1250 trail, don’t hesitate! Its amazing what it can do according to the clinical coordinator who shared this info with me
Link: https://drive.google.com/file/d/1FklxhTXj4N3odFI2lJscdQIUMmQ5u_ZS/view?usp=drivesdk0 -
Thanks, DeeBama, for the information on the OP-1250 trial. Sounds very encouraging.
0 -
Early research in mice...
New therapeutic approach prevents growth of metastatic tumors by putting cancer cells to sleep
...In a previous study, Maria Soledad Sosa from the Icahn School of Medicine at Mount Sinai and Julio A. Aguirre-Ghiso, now at Albert Einstein College of Medicine, discovered that the ability of cancer cells to remain dormant is controlled by a protein called NR2F1. This receptor protein can enter the cell nucleus and turn numerous genes on or off to activate a program that prevents the cancer cells from proliferating.
...In the new JEM study, Sosa and Aguirre-Ghiso's teams used a computer-based screening approach to identify a drug, named C26, that activates NR2F1. The researchers found that treating patient-derived HNSCC cells with C26 boosted the levels of NR2F1 and arrested cell proliferation.
..."Drugs that activate NR2F1 might be particularly useful in breast cancer," says Sosa. "NR2F1 is highly enriched in ER-positive tumors when compared to ER-negative tumors, and activating NR2F1 might be able to suppress reawakening of dormant cancer cells kept in that state by anti-estrogen therapies." However, because C26 treatment elevates the levels of NR2F1, the approach may also be useful for other cancers with inherently low levels of the receptor protein.
0 -
I hope so, Deee, and now I don't remember either...but it was helpful! That expains my not being able to go back and review what you said before I sent my reply!!
0 -
And the very best of luck with the trial! Keep us all posted!
0 -
AlabamaDee's account continues to be compromised. The poster above, AlabamaDeee, which started out as BamaD is NOT the real AlabamaDee. We are in contact with the real AlabamaDee and she has NOT re-registered. Please do not respond to anyone claiming to be AlabamaDee until we notify you.
Please be cautious about sharing your email addresses, or any personal information over PM.
We are working on this issue. Please contact us via PM, or to community@breastcancer.org if you have any concerns.
Warmly,
The Mods
0 -
New cancer therapy from Yibin Kang's [Princeton] lab holds potential to switch off major cancer types without side effects
Cancer biologist Yibin Kang has spent more than 15 years investigating a little-known but deadly gene called MTDH, or metadherin, which enables cancer in two important ways — and which he can now disable, in mice and in human tissue, with a targeted experimental treatment that will be ready for human trials in a few years. His work appears in two papers in today's issue of Nature Cancer...
"You can't find a drug target better than this: MTDH is important for most major human cancers, not important for normal cells, and it can be eliminated with no obvious side effects," said Kang, Princeton's Warner-Lambert/Parke-Davis Professor of Molecular Biology and one of the principal investigators of the Princeton Branch of the Ludwig Institute for Cancer Research.
"In the two papers we are publishing back-to-back today, we identify a compound, show it is effective against cancer, and show that it is very, very effective when combined with chemotherapy and immunotherapy," said Kang...
0 -
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer:
Among premenopausal women with one to three positive lymph nodes and a recurrence score of 25 or lower, those who received chemoendocrine therapy had longer invasive disease–free survival and distant relapse–free survival than those who received endocrine-only therapy, whereas postmenopausal women with similar characteristics did not benefit from adjuvant chemotherapy.
0 -
Definitive Local Therapy in Select Patients With HER2+ de Novo Metastatic Breast Cancer Treated With Dual Anti-HER2 Blockade
- The authors of this retrospective study evaluated the role of local therapy in addition to systemic chemotherapy plus dual anti-HER2 agents in selected HER2-positive de novo metastatic breast cancer. There was a superior 3-year overall survival for patients who received both surgery and radiation compared with those who received surgery alone, radiation alone, or no local therapy.
- Further prospective studies are warranted to confirm the findings for select patients with HER2-positive de novo metastatic breast cancer.
Breast Cancer Res Treat 2021 Nov 17;[EPub Ahead of Print], L Rosier, Y Wang, JH Lee, K Daily{Free access to full article.}0 -
SNO 2021: Neratinib Is Promising for Leptomeningeal Metastases of Heavily Pretreated HER2+ Breast Cancer
Dr. Pellerino concluded that neratinib may be a safe and effective treatment for leptomeningeal metastases of heavily pretreated HER2-positive breast cancer. She remarked, "The study is ongoing with the aim of increasing the sample size to validate preliminary results."
Patients underwent a median of three adjuvant treatments before the onset of leptomeningeal metastases. Three patients developed leptomeningeal metastases alone. The other six harbored leptomeningeal metastases associated with multiple bone metastases. Six-month overall survival was 66.7%. One-year overall survival was 22.3%. Median overall survival was 8 (95% confidence interval 3 - 13) months. Median progression-free survival was 3.5 (95% confidence interval 2 - 6) months from the start of treatment.
Neurological improvement was observed in two of nine patients (22.2%). The remaining four of nine patients (44.5%) achieved neurological stabilization that lasted for a median of 5 (95% confidence interval 2 - 19) months. The best radiological response was stable disease in five of nine patients (55.6%). No complete or partial responses were achieved according to criteria of the Response Assessment in Neuro-Oncology.
This preliminary outcome of an extended-access program was reported at the 2021 Society for Neuro-Oncology's 26th Annual Scientific Meeting and Education Day, from November 18 – 21.
https://www.practiceupdate.com/C/127819/56?elsca1=...
{Free access to this reporting.}
0 -
Breast Cancer Outcomes Following Immediate Breast Reconstruction With Implants Versus Autologous Flaps
- In this retrospective study, there were no significant differences in recurrence rates, distant metastases rates, or survival rates in patients with primary breast cancer who underwent immediate breast reconstruction after nipple-/ skin-sparing mastectomy with either implant-based reconstruction (IBR) or autologous flap reconstruction (AFR).
- Oncologic outcomes were similar in this population following IBR or AFR.
{No charge to access abstract. Charge or subscription to access full article. On my computer, the journal page blocked half the screen if I did not accept ALL cookies. Very annoying. The Practice Update page which offers reporting did NOT do this.}
0 -
A massive 8-year effort finds that much cancer research can't be replicated
"like research in the social sciences, cancer research has a replication problem.
Researchers with the Reproducibility Project: Cancer Biology aimed to replicate 193 experiments from 53 top cancer papers published from 2010 to 2012. But only a quarter of those experiments were able to be reproduced, the team reports in two papers published December 7 in eLife."
https://www.sciencenews.org/article/cancer-biology...
0 -
That's pretty scary!!!
0 -
Duration of Endocrine Therapy in Breast Cancer: How Much of a Good Thing Is Too Much?
Tailored Approach Based on Anatomic and Biologic Risks
We think these recent data are important for clinicians and women with breast cancer and offer a tailored approach based on anatomic and biologic risks. For postmenopausal women with stage I breast cancer, who have lower-risk histologic features or genomic risk scores, 5 years of adjuvant endocrine treatment is likely sufficient, particularly if that includes an aromatase inhibitor at some point. For patients with stage II cancers or limited nodal involvement, they suggest that a treatment course of around 7 years is likely to offer an advantage over 5 years. And, finally, for women with higher-risk tumors by virtue of stage or adverse biology, longer durations of around 10 years remain the standard recommendation. As always, it is important to weigh the benefits of longer treatment against the well-known side effects of therapy, such as arthralgias, osteoporosis, hair thinning, and genitourinary health. Hopefully, patients and clinicians can use these data to make well-informed, data-driven, shared decisions about the best course of therapy.
Dr. Trapani and Dr. Burstein are employed at the Dana-Farber Cancer Institute, Harvard Medical School, Boston.
0 -
Users of AI, we are not crazy, SE exist:
Aromatase inhibitors have been associated with new onset autoimmune diseases.
Our cases suggest a link between aromatase inhibitors and inflammatory myopathies.
Cessation of the aromatase inhibitor should be considered if a myopathy develops.
https://www.sciencedirect.com/science/article/pii/S1297319X21001810?dgcid=rss_sd_all
0 -
Novel Endocrine Drug Slows Previously Treated HR-Positive Breast Cancer
0 -
Anyone know how to get information on SABCS?
There was something related to the trial I'm in but, I have no idea how to find whatever they did.
It should have been Wednesday Night 12/8 at SABCS 5-6:30 PM CT.
"OT1-16-01 A multicenter phase II study of vaccines to prevent recurrence in patients with HER-2 positive breast cancer
Han HS, Disis M, Wesolowski R, Fisher C, Gandhi S, Chan N, Gwin W, Gogineni K, Mick R, Sierra Rodriguez C, Hogue D, Liu H, Costa R, Czerniecki B. Moffitt Cancer Center and Research Institute, Tampa, FL; University of Washington, Seattle, WA; Ohio State University, Columbus, OH; Indiana University School of Medicine, Indianapolis, IN; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Rutgers Cancer Institute of New Jersey, New Brunswick, NY; Emory Winship Cancer Institute, Atlanta, GA; University of Pennsylvania School of Medicine, Philadelphia, PA."
0 -
morrigan, you have to be registered as a delegate. I am one. I will try to get that info for you - I can access talks and presentations but the posters section is not working well for me (& others are having the same problem...)
0 -
Morrigan - the MODs usually post all sorts of information & data after the conference is over.
0 -
Thanks Moth and MinusTwo I'll keep my eye out. I'm also going in for Booster #2 next week so I'll ask them if they have any information as well.
The study is still on going so they were only supposed to present interim findings and, maybe some stuff on Phase 1.
0 -
Healthcare cost of HER2-positive and negative breast tumors in the United States (2012–2035)
The approach to advanced breast cancer has been revolutionized by targeted agents.
•The total cost of HER2-positive patients was estimated for $2,719,542,347 in 2012.•The total estimated cost for HER2-negative patients in 2012 was $8,376,028,459.•In 2035, we estimated a cost of $3.6 and $11.2 bilions for HER2+ and HER2− tumors.•The cost of HER2-negative tumors should be carefully evaluated in the coming years."...our data strongly suggest that cost-analyses should be carefully evaluated in the coming years, aimed to improve the cost-effectiveness of targeted approaches for advanced BC, in particular in patients with HER2-negative tumors. This will be crucial to guarantee the access to cure for all cancer patients and the future economic sustainability of health system."
https://www-sciencedirect-com.ezproxy.liberty.edu/...
https://doi.org/10.1016/j.ctrv.2017.08.005
{This article was evidently published in 2017, but I only recently located a link. It is a bit cringeworthy because the implication seems to me to be that we are not worth the high cost. Of course, it is mostly the drugs.... which, thankfully, are often effective, but which we know to be astronomically unaffordable. The costs/prices they cite are dramatically higher than my shocking EOB's. I can't quite make sense of that. Access to full article seems to be free.}
0 -
Found this interesting from Loma Linda.
Blood Test Finds 50 Types of Cancer
We reported in our August BOB Tales about this test that was invented by Grail, a biotechnology company in Menlo Park, CA. Mayo Clinic has partnered with Grail in the development of the test, which is known as "Galleri." This new test looks for signals in the blood stream that are associated with specific cancers. Cancer-specific information is carried in bloodstream DNA. According to a recent article in Health Care, "The Galleri test uses next generation sequencing and machine-learning algorithms to analyze methylation patterns of cell-free DNA," which helps identify specific cancers. Cells regulate gene expression using DNA methylation. The Galleri test can also pinpoint the location of the disease allowing doctors to select appropriate treatments to target and destroy the cancer.
Having access to a single blood test that can detect 50 types of cancer is significant. The Health Care report states, "Currently recommended cancer screenings in the U.S. cover only five types of cancer and can screen for only one type at a time." Yet, 71 percent of cancer deaths are caused by cancers that are not commonly screened for, according to Grail. False positives with the Galleri test are low, according to researchers, at about one in 200 people tested.
The test is recommended for adults, typically over 50 with an elevated risk for cancer. It should not be a substitute for currently approved tests, such as colonoscopies or mammograms.
Galleri and Mayo Clinic have not received FDA approval for this new test, and insurers do not cover the $949 cost. This blood test is, however, available to the general public and must be administered by a licensed health care provider.
FDA approval for this breakthrough blood test is expected soon and we will report here when that happens.
0 -
The FDA has granted emergency use authorization to an antibody combination called Evusheld that is highly effective at preventing COVID-19 infection in immune compromised patients. Press release here.
https://www.astrazeneca.com/media-centre/press-rel...
0
